Intercept Pharma (ICPT) Announces Phase 3 REGENERATE Study in NASH Met Primary Endpoint

February 19, 2019 7:03 AM
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) announced positive results from its pivotal Phase 3 REGENERATE study of obeticholic acid (OCA) in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Hot FDA News

Next Articles